Of FBT, IBB and XBI, XBI has been the worst performer over the past week, but the best performer year-to-date, scenarios likely attributable to the smaller average market cap of XBI’s holdings. [The Right Time for Biotech ETFs]
“XBI holds just biotechnology stocks yet has more exposure to smaller-caps. Indeed, XBI’s weighted average market cap was $8 billion, compared to IBB’s $44 billion and FBT’s $24 billion,” said S&P Capital IQ.
The research firm does not rate XBI, but has overweight ratings on FBT and IBB.
SPDR S&P Biotech ETF
